{"id":11228,"date":"2020-08-03T00:00:00","date_gmt":"2020-08-03T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/nouveaux-medicaments-pour-le-traitement-de-l-amyloidose-a-chaine-legere\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"nouveaux-medicaments-pour-le-traitement-de-l-amyloidose-a-chaine-legere","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/08\/03\/nouveaux-medicaments-pour-le-traitement-de-l-amyloidose-a-chaine-legere\/","title":{"rendered":"Nouveaux m\u00e9dicaments pour le traitement de l\u2019 amylo\u00efdose  \u00e0 cha\u00eene l\u00e9g\u00e8re"},"content":{"rendered":"<p>L\u2019<strong> amylo\u00efdose<\/strong>&nbsp;AL syst\u00e9mique est un trouble associ\u00e9 au mauvais pliage des prot\u00e9ines qui se caract\u00e9rise par le d\u00e9p\u00f4t de fibrilles amylo\u00efdes insolubles provenant de cha\u00eenes l\u00e9g\u00e8res cin\u00e9tiquement instables. L\u2019obtention d\u2019une r\u00e9ponse h\u00e9matologique rapide et profonde est essentielle \u00e0 la survie \u00e0 long terme.<\/p>\n<p>Cette revue couvre les options de traitement existantes et \u00e9mergentes pour l\u2019AL syst\u00e9mique, divis\u00e9es en traitements anti-plasma cellulaires et \u00e0 base de fibrilles. Pour lire l&rsquo;article au complet, cliquez <strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32731778\/\" target=\"_blank\" rel=\"noopener\">ici<\/a>&nbsp;<\/strong>(en anglais).&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019 amylo\u00efdose&nbsp;AL syst\u00e9mique est un trouble associ\u00e9 au mauvais pliage des prot\u00e9ines qui se caract\u00e9rise par le d\u00e9p\u00f4t de fibrilles amylo\u00efdes insolubles provenant de cha\u00eenes l\u00e9g\u00e8res cin\u00e9tiquement instables. L\u2019obtention d\u2019une r\u00e9ponse h\u00e9matologique rapide et profonde est essentielle \u00e0 la survie \u00e0 long terme. Cette revue couvre les options de traitement existantes et \u00e9mergentes pour l\u2019AL [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11228","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11228"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11228\/revisions"}],"predecessor-version":[{"id":31316,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11228\/revisions\/31316"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}